Molecular pathogenesis of peripheral neuroblastic tumors - sprookjes - yvandenbroek - TriplyDB

Molecular pathogenesis of peripheral neuroblastic tumors

Molecular pathogenesis of peripheral neuroblastic tumors

http://www.wikidata.org/entity/Q28271405

about

Neuroblastoma Crizotinib: A comprehensive review Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase The zebrafish as a model for studying neuroblastoma HOXD-AS1 is a novel lncRNA encoded in HOXD cluster and a marker of neuroblastoma progression revealed via integrative analysis of noncoding transcriptome Autonomic neurocristopathy-associated mutations in PHOX2B dysregulate Sox10 expression Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L mice Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy Preclinical models for neuroblastoma: establishing a baseline for treatment Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells.Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.ALK-driven tumors and targeted therapy: focus on crizotinib Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis.Sensitive detection of viral transcripts in human tumor transcriptomes.Pharmacologic management of high-risk neuroblastoma in children Detection of tumor ALK status in neuroblastoma patients using peripheral blood.Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?Integration of gene expression and methylation to unravel biological networks in glioblastoma patients.Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma.Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.Krüppel-like factor 4 (KLF4) suppresses neuroblastoma cell growth and determines non-tumorigenic lineage differentiation.Functional analysis of the putative tumor suppressor PTPRD in neuroblastoma cells.Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells.The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.Report of neuroblastoma in a set of monozygotic monochorionic twins.GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours.Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Non-Polyalanine Repeat Expansion Mutations.Germline gain-of-function mutations of ALK disrupt central nervous system development.

P2860

Q24617733-62386B87-2B9E-4E25-B8C6-B8975150FE66 Q24624083-814D28B9-E29C-4C49-92B6-7575A1F0E7DE Q27319837-4C028554-1C4D-4938-9799-8A25E7A1694C Q27670943-A7FD5094-D5ED-4477-8A9D-091601159A5A Q27671787-E0AD1945-C856-4575-A967-F913B874E188 Q28070309-6515EF06-165E-4136-9EEB-492477D58D90 Q28652372-05FC1CFA-C73B-4B51-800B-2F8B69C71549 Q30524404-D0D69BC0-4256-4A47-A78D-9C751326D7F7 Q30595148-607E29FA-6F4C-4414-9957-B30B516B88BF Q33652886-3261F10F-666F-4F01-B0E3-E1C2A6FF7374 Q33757079-BCADB182-D0B5-4E50-87E0-2A35734FF28F Q33757085-83B38871-8DF6-4A03-9676-C2CFE9A4E90B Q33859472-AE59CEED-F4D6-4C7C-864E-43BA12CF2340 Q33895108-1549EF96-FE65-4E8C-8032-23BAF0969D8A Q34078699-57471AF4-C4D9-4A7B-8740-04F1C0621341 Q34334471-F784C454-7E94-4E1A-89F5-5BBA5E754218 Q34414378-C292C78C-1BB6-40CF-8322-52D48E3E4B63 Q34977056-66FDBF83-7027-4C65-9B82-4F6EF17598A6 Q35008736-E9D7F47D-1ABA-4606-8D2B-0F358EB12FDE Q35064095-EDC920B1-E2DF-4295-ACCF-5249904F8886 Q35469393-D92A606B-E84A-4626-BC17-B2BEFFDD565A Q35653969-12C5EBA0-4A81-44AC-A6BC-CC23D3B657AD Q35677257-115F96AB-0E98-4262-929E-17572FA60F4E Q35861559-7ACE464A-2EEF-458E-859D-6675096A0753 Q36159646-A87EE014-F1BF-4419-AA47-6D5201188B41 Q36916322-62DE4228-60AB-4DCE-AC89-D25A247FBDC5 Q37259264-66D2EA45-CA37-4158-9EDE-124DEB266872 Q37940719-DBE30B0C-67AC-42D7-BAF2-165D0C23190D Q38096472-126B81C5-0943-47D3-BD23-65401467F74B Q39064478-A6005ED8-905A-42C7-BB14-F365C1A32E95 Q39202569-53752746-D7B9-4A64-BC55-D4CAAD886B16 Q39263442-5E115AEE-E452-423D-A5C7-8DE2C4A88E48 Q39263949-8D4CA724-7C15-47BF-BB64-429D21B429DD Q39351446-96942D6C-32B9-4541-9F29-1FA8A15B72FA Q39475732-B0637D19-DE5E-4B04-83C6-5E898EBE385A Q39606679-461B3535-B8A7-46E0-84E1-A228A841AAD5 Q44636777-E87D0683-C561-4733-A132-78AC9D86E168 Q46180186-0F80A72E-E35B-4FDB-B8AB-A190EC830D87 Q47936860-BA5BDA64-E759-43D3-8C90-D223DD219AA6 Q48860457-373D4379-3E41-4137-8E4F-8345A612C05B

P2860

Molecular pathogenesis of peripheral neuroblastic tumors

http://www.wikidata.org/entity/Q28271405

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Molecular pathogenesis of peripheral neuroblastic tumors

@ast

Molecular pathogenesis of peripheral neuroblastic tumors

@en

Molecular pathogenesis of peripheral neuroblastic tumors

@nl

type

label

Molecular pathogenesis of peripheral neuroblastic tumors

@ast

Molecular pathogenesis of peripheral neuroblastic tumors

@en

Molecular pathogenesis of peripheral neuroblastic tumors

@nl

prefLabel

Molecular pathogenesis of peripheral neuroblastic tumors

@ast

Molecular pathogenesis of peripheral neuroblastic tumors

@en

Molecular pathogenesis of peripheral neuroblastic tumors

@nl

P1433

Q28271405-10CB851E-A2BF-41BC-8A98-A8CCDD9A4D34

P1476

Q28271405-4C1696AC-6413-4018-8677-8F1776687CEB

P2093

Q28271405-F31C32EA-5FD4-4649-AFC8-716FB6F04743

P2860

Q28271405-01B7CD3B-66EC-4063-B9E3-75E1455F3351

Q28271405-02375C2F-7257-4E91-8959-18352EDEF372

Q28271405-03B458B4-FE98-463C-A4C0-487EE904A7F3

Q28271405-03B7CB79-6D27-450E-AE3D-C749D2015521

Q28271405-0530E688-A3DA-442E-A93E-03BF35C61FCD

Q28271405-06048B0D-9181-46FD-ABCE-87252FB7AB34

Q28271405-075ED130-9331-4FB8-88B3-5B564B25FB02

Q28271405-08D3EBDD-6154-4E83-A284-F8B9B2A8EF1A

Q28271405-09FEF995-2E56-4014-AA11-474A3F5F3869

Q28271405-0A39EC29-6EC0-4B42-A7F7-ABE26990EEC6

P2888

Q28271405-BF1DC5FD-C605-4941-BF6B-B4CBA718F6DA

P304

Q28271405-ADB99EE6-A31E-40B8-A38E-3DA83C85B197

P31

Q28271405-58C856E6-3904-4F05-A6C1-E30DE98055E2

P3181

Q28271405-704F39AB-3FA0-4239-8697-016DA7289FE2

P356

Q28271405-EB01B924-B593-46FF-9FCD-8AB744E3588B

P407

Q28271405-FBFCCF3E-5358-4CCC-8992-BD78E571F66A

P433

Q28271405-B2051E33-2478-4E35-90BF-CD1F23F2885C

P478

Q28271405-9372CC68-064E-44DF-85B9-7018F826A094

P50

Q28271405-72ED4F1A-922C-4C77-AEC3-78D57B9BE42B

Q28271405-A89D5208-D86D-4D59-BC82-EAF47D1C8185

P577

Q28271405-CC52E1FE-2C1E-4801-8A48-9A44589947CE

P6179

Q28271405-DB7838AE-3D09-4673-A33A-A833A4132A1E

P698

Q28271405-F78DA62A-3954-4B61-9350-8949E3C03A78

P921

Q28271405-C7757681-D06F-462F-8C25-2125E0424863

P3181

P356

P1433

P1476

Molecular pathogenesis of peripheral neuroblastic tumors

@en

P2093

G Schleiermacher

http://www.w3.org/2001/XMLSchema#string

P2860

Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome

Anaplastic lymphoma kinase: signalling in development and disease

Copy number variation at 1q21.1 associated with neuroblastoma

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

Identification of ALK as a major familial neuroblastoma predisposition gene

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma

cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

P2888

P304

1566-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3065775

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/ONC.2009.518

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Isabelle Janoueix-Lerosey

Olivier Delattre

P577

2010-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032249338

http://www.w3.org/2001/XMLSchema#string

P698

20101209

http://www.w3.org/2001/XMLSchema#string

P921